HOME>News & Media>LATUDA Press Room
Healthy bodies, healthy lives

On October 28, 2010, the U.S. FDA approved Sunovion's Latuda® (lurasidone HCl) tablets for the treatment of patients with schizophrenia. LATUDA is available by prescription in pharmacies across the United States and Puerto Rico. For more information please visit www.LATUDA.com.

 

 Date  Title
10/30/12 Sunovion Pharmaceuticals Inc. Announces FDA Acceptance of Two Supplemental New Drug Applications for the Use of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Depressive Episodes Associated with Bipolar I Disorder
09/06/12 Sunovion Pharmaceuticals Files Two Supplemental New Drug Applications Seeking Approval for the use of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Depressive Episodes Associated with Bipolar I Disorder
05/09/12 New Study Shows Patients Can Effectively be Switched to Latuda® (lurasidone HCl) from Other Antipsychotic Agents
05/07/12 Dainippon Sumitomo Pharma Co. Reports that Latuda (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression
05/05/12 Latuda® (lurasidone HCl) Label Updated With Expanded Dosing Range Providing Added Flexibility for the Treatment of Patients with Schizophrenia
10/27/11 LATUDA® (lurasidone HCl) Shown to be Non-Inferior to SEROQUEL XR® (quetiapine fumarate XR) in Risk for Relapse in a 12-Month, Double-Blind Extension Study of Adult Patients with Schizophrenia
05/17/11 Latuda® (lurasidone HCl) was Associated with Low Rates of Weight Gain and Metabolic Changes in Patients with Schizophrenia in Data Presented at the 164th Meeting of the American Psychiatric Association
02/03/11 Once-daily Latuda® (lurasidone HCl) Now Available in Pharmacies Nationwide for the Treatment of Patients with Schizophrenia
12/08/10 Latuda® (lurasidone HCl) Significantly Improves Symptoms of Schizophrenia in Fifth Positive Placebo-Controlled Study
10/28/10 FDA approves once-daily LATUDA® (lurasidone HCl) for the treatment of patients with schizophrenia

Corporate Communications
508-357-7740
84 Waterford Drive
Marlborough, MA 01752
communications@sunovion.com

Home | Who We Are | Our Products | For Our Patients | Working at Sunovion | For Healthcare Professionals | Site Map | Terms of Use | Privacy Policy | About DSP
Sunovion is a trademark of Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan. © 2012 Sunovion Pharmaceuticals Inc., Marlborough, MA 01752. All rights reserved.